Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: Di Leo A, Jerusalem G, Petruzelka L, et al (Hosp of Prato, Italy; Centre Hospitalier Universitaire Sart Tilman, Liége, Belgium; AZ. Klina, Brasschaat, Belgium; Et al) J Clin Oncol 28:4594-4600, 2010

V. C. Jordan

doi:10.1016/j.breastdis.2012.04.003

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: Di Leo A, Jerusalem G, Petruzelka L, et al (Hosp of Prato, Italy; Centre Hospitalier Universitaire Sart Tilman, Liége, Belgium; AZ. Klina, Brasschaat, Belgium; Et al) J Clin Oncol 28:4594-4600, 2010

Breast Medical Oncology

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	190-191
Number of pages	2
Journal	Breast Diseases
Volume	23
Issue number	2
DOIs	https://doi.org/10.1016/j.breastdis.2012.04.003
State	Published - 2012

ASJC Scopus subject areas

Surgery
Oncology

Access to Document

10.1016/j.breastdis.2012.04.003

Cite this

Jordan, V. C. (2012). Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: Di Leo A, Jerusalem G, Petruzelka L, et al (Hosp of Prato, Italy; Centre Hospitalier Universitaire Sart Tilman, Liége, Belgium; AZ. Klina, Brasschaat, Belgium; Et al) J Clin Oncol 28:4594-4600, 2010. Breast Diseases, 23(2), 190-191. https://doi.org/10.1016/j.breastdis.2012.04.003

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: Di Leo A, Jerusalem G, Petruzelka L, et al (Hosp of Prato, Italy; Centre Hospitalier Universitaire Sart Tilman, Liége, Belgium; AZ. Klina, Brasschaat, Belgium; Et al) J Clin Oncol 28:4594-4600, 2010. / Jordan, V. C.
In: Breast Diseases, Vol. 23, No. 2, 2012, p. 190-191.

Research output: Contribution to journal › Comment/debate › peer-review

Jordan, VC 2012, 'Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: Di Leo A, Jerusalem G, Petruzelka L, et al (Hosp of Prato, Italy; Centre Hospitalier Universitaire Sart Tilman, Liége, Belgium; AZ. Klina, Brasschaat, Belgium; Et al) J Clin Oncol 28:4594-4600, 2010', Breast Diseases, vol. 23, no. 2, pp. 190-191. https://doi.org/10.1016/j.breastdis.2012.04.003

Jordan VC. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: Di Leo A, Jerusalem G, Petruzelka L, et al (Hosp of Prato, Italy; Centre Hospitalier Universitaire Sart Tilman, Liége, Belgium; AZ. Klina, Brasschaat, Belgium; Et al) J Clin Oncol 28:4594-4600, 2010. Breast Diseases. 2012;23(2):190-191. doi: 10.1016/j.breastdis.2012.04.003

Jordan, V. C. / Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer : Di Leo A, Jerusalem G, Petruzelka L, et al (Hosp of Prato, Italy; Centre Hospitalier Universitaire Sart Tilman, Liége, Belgium; AZ. Klina, Brasschaat, Belgium; Et al) J Clin Oncol 28:4594-4600, 2010. In: Breast Diseases. 2012 ; Vol. 23, No. 2. pp. 190-191.

@article{0de81464434545879bae7bc275b33f37,

title = "Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: Di Leo A, Jerusalem G, Petruzelka L, et al (Hosp of Prato, Italy; Centre Hospitalier Universitaire Sart Tilman, Li{\'e}ge, Belgium; AZ. Klina, Brasschaat, Belgium; Et al) J Clin Oncol 28:4594-4600, 2010",

author = "Jordan, {V. C.}",

year = "2012",

doi = "10.1016/j.breastdis.2012.04.003",

language = "English (US)",

volume = "23",

pages = "190--191",

journal = "Breast Diseases",

issn = "1043-321X",

publisher = "Academic Press Inc.",

number = "2",

}

TY - JOUR

T1 - Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer

T2 - Di Leo A, Jerusalem G, Petruzelka L, et al (Hosp of Prato, Italy; Centre Hospitalier Universitaire Sart Tilman, Liége, Belgium; AZ. Klina, Brasschaat, Belgium; Et al) J Clin Oncol 28:4594-4600, 2010

AU - Jordan, V. C.

PY - 2012

Y1 - 2012

UR - http://www.scopus.com/inward/record.url?scp=84862091337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862091337&partnerID=8YFLogxK

U2 - 10.1016/j.breastdis.2012.04.003

DO - 10.1016/j.breastdis.2012.04.003

M3 - Comment/debate

AN - SCOPUS:84862091337

SN - 1043-321X

VL - 23

SP - 190

EP - 191

JO - Breast Diseases

JF - Breast Diseases

IS - 2

ER -

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this